BioPharmX Corporation (NASDAQ:BPMX) Expected to Post Earnings of -$0.31 Per Share

Equities analysts forecast that BioPharmX Corporation (NASDAQ:BPMX) will post ($0.31) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for BioPharmX’s earnings. BioPharmX reported earnings of ($0.50) per share in the same quarter last year, which suggests a positive year over year growth rate of 38%. The company is expected to issue its next quarterly earnings results on Thursday, August 29th.

On average, analysts expect that BioPharmX will report full-year earnings of ($0.65) per share for the current year. For the next fiscal year, analysts expect that the business will report earnings of ($0.25) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow BioPharmX.

BioPharmX (NASDAQ:BPMX) last posted its earnings results on Tuesday, June 11th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.13).

Shares of NASDAQ:BPMX traded down $0.02 during midday trading on Friday, hitting $0.36. The company’s stock had a trading volume of 386,474 shares, compared to its average volume of 658,221. The stock’s 50 day moving average is $0.59. BioPharmX has a fifty-two week low of $0.35 and a fifty-two week high of $6.75.

BioPharmX Company Profile

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Further Reading: Straddles

Get a free copy of the Zacks research report on BioPharmX (BPMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related companies with's FREE daily email newsletter.